SCHEMBL1384475

SCHEMBL1384475

NC(=O)c1n[nH]c2ncccc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CAMKK2 Q96RR4 2/20 0.46
KDM4E B2RXH2 4/20 0.41
IKBKB O14920 1/20 0.41
CHUK O15111 1/20 0.41
LIMK1 P53667 1/20 0.41
RPS6KB1 P23443 2/20 0.40
MAPK10 P53779 1/20 0.40
HSD17B10 Q99714 1/20 0.40
MAP2K1 Q02750 1/20 0.40
RIPK1 Q13546 1/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPK1 P28482 1/20 0.39
PARP1 P09874 2/20 0.39
AURKA O14965 1/20 0.39
GSK3A P49840 1/20 0.38
GSK3B P49841 1/20 0.38
YTHDC1 Q96MU7 1/20 0.38
FEN1 P39748 1/20 0.38
STAT3 P40763 1/20 0.38
HIF1A Q16665 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29732854 1.00 CAMKK2 (0.46) CAMKK2KDM4EIKBKBCHUKLIMK1
SCHEMBL6338427 0.89 CAMKK2 (0.43) CAMKK2KDM4EIKBKBCHUKLIMK1
SCHEMBL28098788 0.86 MAP2K1 (0.41) CAMKK2KDM4EMAPK10HSD17B10MAP2K1
SCHEMBL1048847 0.84 KDM4E (0.47) CAMKK2KDM4EMAPK10HSD17B10MAP2K1
SCHEMBL29623160 0.84 KDM4E (0.47) CAMKK2KDM4EMAPK10HSD17B10MAP2K1
SCHEMBL4667694 0.84 CAMKK2 (0.39) CAMKK2KDM4EIKBKBCHUKLIMK1
SCHEMBL1554784 0.83 KDM4E (0.60) KDM4EMAPK10HSD17B10ALDH1A1MAPK1
SCHEMBL30884587 0.83 CAMKK2 (0.36) CAMKK2KDM4EMAPK10HSD17B10MAP2K1
SCHEMBL3638218 0.83 CAMKK2 (0.36) CAMKK2KDM4EMAPK10HSD17B10MAP2K1
SCHEMBL5924436 0.83 MAP2K1 (0.43) CAMKK2KDM4EMAPK10HSD17B10MAP2K1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4460301-A1 SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES Universität zu Köln (DE) 2024-11-13 EP claimed
EP-3760625-B1 BICYCLIC LACTAMS AS RECEPTOR-INTERACTING PROTEIN-1 (RIP1) KINASE INHIBITORS FOR TREATING E.G. INFLAMMATORY DISEASES HOFFMANN LA ROCHE (CH) 2024-03-27 EP claimed
WO-2023131576-A1 SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES UNIVERSITÄT ZU KÖLN (DE) 2023-07-13 WO claimed
EP-2699576-A1 PYRAZOLOSPIROKETONE DERIVATIVES FOR USE AS ACETYL - COA CARBOXYLASE INHIBITORS Pfizer Inc (US) 2014-02-26 EP claimed
WO-2012143813-A1 PYRAZOLOSPIROKETONE DERIVATIVES FOR USE AS ACETYL - COA CARBOXYLASE INHIBITORS PFIZER INC. (US) 2012-10-26 WO claimed
JP-4814783-B2 2011-11-16 JP claimed
EP-2265335-A1 INDAZOLE DERIVATIVES Pfizer Inc. (US) 2010-12-29 EP claimed
WO-2009106982-A1 INDAZOLE DERIVATIVES PFIZER INC. (US) 2009-09-03 WO claimed
WO-2009106980-A2 INDAZOLE DERIVATIVES PFIZER INC. (US) 2009-09-03 WO claimed
EP-4525853-A1 METHODS AND COMPOSITIONS FOR TREATING FATTY LIVER AND VIRAL INFECTIONS The Board of Trustees of the Leland Stanford Junior University (US) 2025-03-26 EP disclosed
EP-4460301-A1 SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES Universität zu Köln (DE) 2024-11-13 EP disclosed
WO-2023225324-A1 METHODS AND COMPOSITIONS FOR TREATING FATTY LIVER AND VIRAL INFECTIONS THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2023-11-23 WO disclosed
WO-2023131576-A1 SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES UNIVERSITÄT ZU KÖLN (DE) 2023-07-13 WO disclosed
WO-2023025109-A1 TOLL-LIKE RECEPTOR INHIBITOR AND PREPARATION AND APPLICATION THEREOF 上海维申医药有限公司 2023-03-02 WO disclosed
JP-2009196932-A PYRAZOLO[3,4-b]PYRIDINE AMIDE COMPOUND WITH HISTAMINE H4 RECEPTOR ANTAGONISTIC ACTION KOWA CO 2009-09-03 JP disclosed
WO-2009106982-A1 INDAZOLE DERIVATIVES PFIZER INC. (US) 2009-09-03 WO disclosed
WO-2009106980-A2 INDAZOLE DERIVATIVES PFIZER INC. (US) 2009-09-03 WO disclosed
EP-2089018-A2 METHODS OF TREATING COGNITIVE IMPAIRMENT AND DEMENTIA Lexicon Pharmaceuticals, Inc. (US) 2009-08-19 EP disclosed
WO-2008067121-A2 METHODS OF TREATING COGNITIVE IMPAIRMENT AND DEMENTIA LEXICON PHARMACEUTICALS, INC. (US) 2008-06-05 WO disclosed
WO-2006124897-A2 METHODS AND COMPOSITIONS FOR IMPROVING COGNITION LEXICON GENETICS INCORPORATED (US) 2006-11-23 WO disclosed